An Open-label, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Inclacumab (Primary)
- Indications Acute coronary syndromes; Myocardial infarction; Peripheral vascular disorders
- Focus Pharmacokinetics
- Sponsors Roche
- 10 Feb 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
- 18 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Sep 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.